# A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

Study · id `cardio:ct-nct01958671` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01958671](<https://clinicaltrials.gov/study/NCT01958671>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01958671

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 461 participants.

## Technical summary

Registry record NCT01958671. Randomized; double masking; primary purpose treatment. Start 2013-10-09 (actual); primary completion 2016-07-28 (actual). Results posted on 2017-09-29.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 461 participants (enrolled count; ClinicalTrials.gov record NCT01958671, source copy `cardio:ctgov-nct01958671-2017-09-29`, retrieved 2026-10-26)
- Started: 2013-10-09 (actual) (ClinicalTrials.gov record NCT01958671, source copy `cardio:ctgov-nct01958671-2017-09-29`, retrieved 2026-10-26)
- Primary completion: 2016-07-28 (actual) (ClinicalTrials.gov record NCT01958671, source copy `cardio:ctgov-nct01958671-2017-09-29`, retrieved 2026-10-26)
- Completion: 2016-07-28 (actual) (ClinicalTrials.gov record NCT01958671, source copy `cardio:ctgov-nct01958671-2017-09-29`, retrieved 2026-10-26)
- Results first posted: 2017-09-29 (ClinicalTrials.gov record NCT01958671, source copy `cardio:ctgov-nct01958671-2017-09-29`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01958671-2017-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ertugliflozin 5 mg
- Intervention (Drug): Ertugliflozin 10 mg
- Intervention (Drug): Placebo to Ertugliflozin
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo to Metformin
- Intervention (Drug): Glimepiride
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone (`cardio:pubmed-28116776`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study (`cardio:pubmed-29419917`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e3ce6c46ce0536959c530a5e7876ec5748eda1ae461f84b15e8c366d280bd408
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
